Saudi Arabia Hypersomnia Therapeutics Market Analysis

Saudi Arabia Hypersomnia Therapeutics Market Executive Summary

The Saudi Arabia Hypersomnia Therapeutics Market is at around $184.89 Mn in 2023 and is projected to reach $278.01 Mn in 2030, exhibiting a CAGR of 6% during the forecast period.

Hypersomnia is a group of neurological disorders characterized by excessive daytime sleepiness, despite getting enough sleep at night. This can significantly impair daily functioning and reduce quality of life. While the exact causes are still being researched, hypersomnia can be linked to underlying medical conditions, neurological disorders, or disruptions in sleep regulation mechanisms. People with hypersomnia often experience symptoms such as not feeling refreshed upon waking, feeling groggy and slow for extended periods after waking, and an excessive need for sleep despite sleeping for long periods. Chronic headaches, loss of appetite, excessive sweating, and depression have also been reported. Treatment for hypersomnia focuses on managing daytime sleepiness. This can involve adopting healthy lifestyle practices like eating well and exercising regularly. Medications like stimulants can also be prescribed to promote wakefulness. In some cases, cognitive behavioral therapy for insomnia (CBT-I) can help address underlying sleep habits that contribute to hypersomnia.

The prevalence of excessive daytime sleepiness, a key symptom of hypersomnia, is 20% in Saudi Arabia. The market therefore is driven by significant factors like the increasing awareness about hypersomnia disorders, growing aging population, and lifestyle changes. However, high costs of treatment, limited accessibility to specialized healthcare services, and strict regulatory approval restrict the market growth.

The leading pharmaceutical companies include Pfizer for the treatment of hypersomnia disorders in Saudi Arabia. Sanofi, Novartis, and Mepha are also significant contributors to the hypersomnia therapeutics landscape, with continuous research and development activities.

Market Dynamics

Market Growth Drivers

Increasing Awareness about Hypersomnia Disorders: Increased public awareness campaigns and healthcare professional education are leading to more accurate diagnoses, raising the potential patient pool for these medications. Saudi Arabia has participated in World Sleep Day celebrations organized by the World Sleep Society. Awareness campaigns are organized in Riyadh that involve setting up counters to educate the public about the importance of healthy sleep practices and common sleep disorders.

Expanding Geriatric Population: Hypersomnia may be more common in elderly individuals because of alterations in sleep structure and existing health issues. As the elderly population makes up 3% of the total population, the occurrence of hypersomnia disorders is projected to increase, leading to a higher need for specialized treatment options designed for the specific requirements of older individuals.

Lifestyle changes:  Saudi Arabia is undergoing a transition towards city living and adjustments in work-life harmony. A growing number of people working in the service industry face shift work and long hours, impacting circadian rhythms and resulting in a rise in hypersomnia cases.

Market Restraints

High costs of treatment: Hypersomnia treatments pose a significant financial barrier for many patients, especially those in lower socioeconomic circumstances. These costs significantly burden patients and healthcare systems financially. Although these medicines have increased effectiveness, their high price hinders access for certain individuals.

Strict Regulatory Approval Process: Saudi Arabia has a lengthy and challenging regulatory process for approving new drugs. This slows down the entry of potentially more effective medications into the market, limiting treatment options for patients and hindering market expansion.

Limited Accessibility to Specialized Healthcare Services: In rural districts, particularly those in less populated regions, the availability of sleep disorder clinics, neurologists, and sleep medicine doctors is scarce. In Saudi Arabia, hypersomnia often goes unidentified due to the challenges in diagnosing, treating, and managing the condition.

Regulatory Landscape and Reimbursement Scenario

The regulatory obligations are overseen primarily by the Saudi Food and Drug Authority (SFDA). SFDA aims to minimize health risks associated with the consumption or use of unsafe or substandard products. It educates and informs consumers about health and safety issues related to food, drugs, and other regulated products. It also collaborates with international regulatory agencies, organizations, and stakeholders to exchange information and harmonize standards.

The Council of Health Insurance in Saudi Arabia oversees health insurance regulations and policies for the private sector. At the same time, the Ministry of Health (MOH) is responsible for providing healthcare services and implementing healthcare policies for citizens through its healthcare facilities and programs.

Obtaining a license for drugs and pharmaceuticals in Saudi Arabia involves gathering all the necessary information, including comprehensive pre-clinical and clinical trial data demonstrating the drug's safety and efficacy. The SFDA will thoroughly review your application and all submitted data. The approval process can be lengthy, potentially taking several months to a year or more.

Competitive Landscape

Key Players

Here are some of the major key players in the Saudi Arabia Hypersomnia Therapeutics Market:

• Pfizer
• Sanofi
• Novartis
• Teva
• Takeda Pharmaceuticals
• Merck
• Mepha
• Novo Nordisk
• Fisher and Paykel Healthcare
• GlaxoSmithKline
• Hikma